Home › Companies › CING

Cingulate

CING Lead: NDA Submitted 5 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-18

Pipeline (1 active programs)

dexmethylphenidate

dexmethylphenidate HCl · CTx-1301

Small Molecule

Attention Deficit Hyperactivity Disorder NDA Submitted oral BDD Pharma

Technology platforms

PTR · BDD Pharma

Precision Timed Release (PTR) drug delivery platform — proprietary multi-core tablet technology incorporating an Erosion Barrier Layer (EBL) to deliver precisely timed pulsatile drug releases; focus areas: ADHD and anxiety disorders. EBL formulation (Oralogik) licensed from BDD Pharma.

Precision Timed Release

PTR-enabled tri-modal release delivery platform for oral tablets; designed to provide morning onset and sustained active-day coverage in a single once-daily tablet; focus area: ADHD and potentially other CNS conditions

Biotech Distilled coverage (5)

2026-06-02 UPDATE: Cingulate (CING) - The CRL Lands, the Tripwire Arms
2026-05-15 UPDATE: Cingulate (CING) - The CMC Shoe Drops 17 Days Before PDUFA
2026-04-05 UPDATE: Cingulate (CING) - Institutional Adult Supervision Enters the Boardroom 🔒 Paid
2026-03-28 UPDATE: Cingulate (CING) - The Dilution Gap Just Became a Chasm 🔒 Paid
2026-03-23 Cingulate (CING) - Scientific Deep Dive on CTx-1301 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.